Ironwood Pharmaceuticals
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Ironwood Pharmaceuticals (IRWD) | 778.09M | 5.22 | -8.01 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 7.2% below Morningstar's fair value estimate.
Fair value
Ironwood Pharmaceuticals Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $5.04 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's profitability bolsters our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 21.8% sits in the top 10% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.
Conversely, the company's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's current ratio of 6.5, for example, falls in the top 10% globally. This suggests that management of working capital may be "lazy", tying up valuable capital that could be considered excessive and leading to a lower return on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.
Ironwood Pharmaceuticals discussion 0 comments